Regenxbio (RGNX) Net Margin (2014 - 2026)

Regenxbio's Net Margin history runs 12 years deep, the most recent figure standing at 330.86% for Q4 2025.

• In Q4 2025, Net Margin rose 64489.0% year-over-year to 330.86%; the TTM figure through Dec 2025 stood at 26.03% (up 28240.0% YoY), while the FY2025 annual figure was 342.72%, down 6598.0% from the prior year.
• Net Margin for Q4 2025 stood at 330.86%, up from 220.23% in the prior quarter.
• The five-year high for Net Margin was 890.75% in Q4 2022, with the low at 481.95% in Q1 2024.
• The 5-year median for Net Margin is 254.98% (2021), against an average of 165.35%.
• The sharpest annual moves came in 2022 and 2023: Net Margin surged 81700 bps in 2022, then tumbled 117423 bps in 2023.
• Regenxbio's Net Margin stood at 73.75% in 2021, then surged by 1108 bps to 890.75% in 2022, then sank by 132 bps to 283.48% in 2023, then dropped by 11 bps to 314.04% in 2024, then surged by 205 bps to 330.86% in 2025.
• Business Quant data shows RGNX's Net Margin at 330.86% in Q4 2025, 220.23% in Q3 2025, and 331.91% in Q2 2025.